A B S T RAC T In the present study, terminal deoxynucleotidyltransferase was examined in the peripheral blood and (or) bone marrow of 115 children with a variety of neoplastic, hematologic, and other unrelated disorders. Terminal deoxynucleotidyltransferase activity was present at 4.08+0.74 U/108 cells in 23 morphologically normal bone marrow samples from childhood controls. Terminal transferase was present at >23 U/108 nucleated cells and at >31 U/108 blasts in the bone marrow of all children with acute lymphoblastic leukemia studied at initial diagnosis and at disease relapse. Terminal deoxynucleotidyltransferase was detectable at low levels, <7.5 U/108 cells, in all remission marrow samples. Bone marrow terminal transferase activity was markedly elevated in all untreated acute lymphoblastic leukemia patients, whereas low levels which were difficult to interpret were present in the peripheral blood samples oftwo patients at diagnosis and six patients at relapse who had low absolute lymphoblast counts. Because of greater variation in the lymphoblast content of peripheral blood, bone marrow assays are more reliable in detecting disease activity. Marrow terminal deoxynucleotidyltransferase values obtained during the active phase of acute lymphoblastic leukemia were significantly greater than those found in other types of leukemia, bone marrow malignancies, and hematologic disorders. Terminal transferase determinations in blast cells of two patients with leukemic conversion of non-Hodgkin's lymphoma and in tumor cells from one patient with Burkitt's lymphoma were within the control range. These data further define the usefulness of terminal deoxynucleotidyltransferase assay in the differentiation and classification of hematologic malignancies.
INTRODUCTION
Recent evidence suggests that terminal deoxynucleotidyltransferase (TdT)l may be a biochemical marker useful for classifying leukemias (1) (2) (3) (4) (5) (6) . This unusual deoxynucleotide-polymerizing activity is normally present at high levels only in the thymus (7) and at low levels in the bone marrow (5), but has not been detected in circulating or mitogen-stimulated lymphocytes (5) . Identification of TdT activity in circulating blast cells (1) (2) (3) (4) (5) (6) and cell lines (8-10) from acute lymphoblastic leukemia (ALL) patients, and in some cases of chronic myelogenous leukemia in blastic crisis (2, 6, (10) (11) (12) , has raised the speculation that it may be localized in a primitive hematopoietic stem cell (5) . In vitro, terminal transferase catalyzes the addition of deoxynucleoside triphosphates to the 3'-hydroxyl ends of oligo-or polydeoxynucleotide initiators without template instruction (13) . Since an activity of this kind might cause modification of DNA sequence, it has been suggested that the enzyme could participate in somatic diversification of lymphoid precursors during differentiation (13) (14) (15) .
TdT levels in peripheral blood lymphoid cells of patients with ALL at different phases of the disease have been reported (4) . The purpose of the present study was to examine TdT activity in bone marrow and peripheral blood from children with acute leukemia of various cell types, solid tumors, nonneoplastic hematologic disorders, and other unre-lated conditions in which a bone marrow examination was included in the patient's diagnostic evaluation. The results to be reported here establish the range of TdT activity normally present in the bone marrow of children of varying ages, and define the specificity of the enzyme in differentiating neoplastic disease.
METHODS
Patients. Peripheral blood lymphoid cells and (or) bone marrow cells were examined in 62 children with ALL. 20 of the patients were studied initially at diagnosis; 18 patients were in complete disease remission on chemotherapy; 12 patients were in complete disease remission and off chemotherapy; and 12 patients were evaluated during disease relapse. Patients were treated according to a standardized ALL chemotherapy protocol (4) consisting of induction therapy, central nervous system prophylaxis, and multiple agent maintenance therapy continuing for 3 yr or until relapse.
Additional blood, bone marrow, and (or) tumor specimens were assayed from 8 (16) . The cells were aspirated from the interface and washed twice in HBSS. Contaminating monocytes were removed using carbonyl iron powder as described by Raff (17) . An aliquot of the purified lymphoid cells was collected on glass slides using a cytocentrifuge and the cells were stained with Wright-Giemsa. Some cells appeared damaged by the gradient separation and preservation of morphological detail was such that mature and leukemic lymphoid cells could not always be distinguished although contamination of the lymphoid fraction by monocytes or polymorphonuclear leukocytes was easily monitored. Bone marrow cells were separated by dextran sedimentation as described for peripheral blood, but were not processed on Ficoll-Hypaque gradients. An aliquot of purified nucleated cells from marrow and (or) blood was counted and processed directly for assay of cell surface markers. Another aliquot was stored as a cell pellet at -700C for later TdT assay.
Sheep erythrocyte (E) rosette assay. E-rosette assays were performed in duplicate according to the method of Bentwich et al. (18) . 0. (23) , the assay is now assumed to be specific for this enzyme. Table I . The mean age of the patients was 5.8 yr and the male to female ratio was 1:1. Bone marrow lymphoblasts varied from 22 to 99% (mean 86%) and peripheral blood lymphoblasts ranged from 5 to 94% (mean 56%) with the absolute lymphoblast count varying from 110 to 278,000/mm3. TdT activity was markedly elevated in bone marrow samples from all patients examined at diagnosis, (range 30. (Table I) at initial diagnosis, but were significantly higher than the mean peripheral blood and bone marrow values of controls (P < 0.025, P < 0.001).
Testicular relapse preceded hematologic relapse by 2 mo in patient 7 (Table IV) (Table V) . Bone marrow specimens from two patients, one with disseminated neuroblastoma and one with disseminated rhabdomyosarcoma (Table V) (Table V) . The highest bone marrow activity observed was 12.00 U/108 cells in a 2-yr-old male who has no evidence of hematological abnormalities 1 yr after spontaneous remission of ITP. Assays of bone marrow specimens from five children with aplastic anemia revealed a range of TdT activity from 1.21 to 3.40 U/108 cells, mean±SE = 2.36 ±0.46 U/108 cells (Table V) . There was no significant correlation with age and values obtained in patients with ITP, and aplastic anemia did not differ significantly from the control group of hematologically normal patients.
Controls. Children 1 wk-14 yr of age requiring a bone marrow examination in their diagnostic evaluation and in whom no evidence of-neoplastic or primary hematologic disorder was present were used as controls for this study. 23 Follow-up studies on a previously reported series of ALL patients (4) now reveal that four of the seven patients evaluated at diagnosis relapsed after 6-11 mo. Three of these patients were males with Tmarker lymphoblasts, mediastinal masses, and initial blast counts greater than 50,000/mm3. The fourth patient was a 17-yr-old female with null lymphoblasts and an initial blast count of 366,000/mm3. In this group of four patients who relapsed, TdT levels ranged from 8 to 210 U/108 peripheral lymphoid cells at the time of diagnosis, indicating that TdT levels alone are not predictive of ultimate prognosis in ALL. Determinations of lymphoblast surface markers were performed at the time of relapse in two of the four patients from the previously reported series. Lymphoblast characteristics at relapse were unchanged from diagnosis in patient 10 (Table IV) with null lymphoblasts and in patient 11 (Table IV) with T-marker lymphoblasts predominating. Patient 7 (Table IV) who was not included in the initial series had T-marker lymphoblasts both at diagnosis and relapse in peripheral blood and testicular infiltrates. Combining data from both series of ALL patients, no statistical difference was found between the mean peripheral blood TdT values in T-lymphoblastic leukemia (40.9+8.8 U/108 cells) and null cell ALL (86.1±18.8 U/108 cells), P > 0.10.
Bone marrow TdT activity was markedly elevated at the time of diagnosis in all patients classified as ALL on the basis of cytological and cytochemical analysis. Morphologic classification of the cell type was assigned before obtaining the results of bone marrow TdT assay in every patient in this report. Bone marrow TdT activity in ALL at diagnosis was higher than bone marrow activity from children classified as acute myeloblastic leukemia, acute myelomonoblastic leukemia, acute undifferentiated leukemia, and in disseminated neuroblastoma and disseminated rhabdomyosarcoma. These biochemical findings indicate that TdT activity may be a useful adjunct in differentiating neoplastic bone marrow cell populations in children.
The observation of very low TdT activity in bone marrow blasts of two children with leukemic transformation of previously isolated non-Hodgkin's lymphoma and in tumor cells from a biopsy of Burkitt's lymphoma is evidence that TdT may also be a useful marker in differentiating malignant cell populations of lymphoid origin. The blood and bone marrow blasts from both patients at the time of leukemic transformation resembled lymphoblasts of ALL by morphological and histochemical evaluation and were typed as null cells by marker analysis. McCaffrey et al. (2) likewise found low levels of TdT in peripheral blood samples of two patients with lymphosarcoma-cell leukemia.
We have observed levels of TdT activity ranging from 0.05 to 1,000 nmol nucleotide incorporated/h per 108 cells, demonstrating the sensitivity of the analytical conditions over four orders of magnitude. Our assay appears to be somewhat more sensitive than assays used by others. We feel this is because sonication in the presence of 0.25 M phosphate buffer provides optimal extraction of the enzyme and the use of crude extract avoids fractionation losses. The initiator, poly d(pA)-, and [3H]dGTP substrate minimize the effects of nucleases by forming a "nuclease-insensitive" product for assay. Cacodylate buffer is optimal for TdT but inhibits DNA polymerases a and f3, minimizing the possibility of low level interference by these activities. Nucleotide at a concentration of 1 mM is required for maximal reaction velocity. In an attempt to make the assay practical and economical for large numbers of samples, 1 mM [3H]dGTP at a spec act of 100 cpm/pmol is routinely used. Under these conditions, samples incorporating 1 nmol nucleotide/h per 108 cells (1 U) develop counts that are only two-to three-times background radioactivity, so samples assaying less than that cannot be reliably distinguished from zero activity. Increasing the specific activity of the nucleotide to 1,000 cpm/pmol decreases the detection limit to about 0.05 U/108 cells.
TdT activity was detectable at 0.07-1.61 U/108 cells in only 4 of the 11 peripheral blood samples from childhood controls and the remainder were <0.05 U/108 cells. Although the biological significance of these low values was not explored in this study, perhaps these levels reflect enzyme activity in the circulating hematopoietic stem cells described by Barr et al. (29) . That is, it might be possible to assay for this stem cell activity in normal individuals by using other concentrative and separative procedures (30) not used in the present study.
The data presented indicate that limitations must be applied to clinical interpretation of blood and bone marrow TdT activity since enzyme levels of 13 
